In This Story
Prestige Consumer Healthcare Inc. (PBH+0.10%) has submitted its 10-Q filing for the quarterly period ended December 31, 2024.
The filing includes financial statements for the quarter, indicating an increase in total revenues to $290.3 million, up from $282.7 million in the same quarter the previous year. This increase was driven by growth in the International OTC Healthcare segment.
Gross profit for the quarter was $161.0 million, compared to $157.9 million in the previous year. The gross profit margin decreased slightly to 55.5% from 55.9%, primarily due to increased supply chain costs.
The North American OTC Healthcare segment reported revenues of $238.9 million, a slight increase from $236.6 million in the previous year. The increase was mainly due to higher sales in the Gastrointestinal and Dermatologicals categories.
The International OTC Healthcare segment saw revenues rise to $51.4 million, up from $46.2 million, driven by increased sales in the Gastrointestinal category.
Operating expenses for the quarter included advertising and marketing costs of $37.9 million, down from $39.5 million, and general and administrative expenses of $26.2 million, consistent with the previous year.
Net income for the quarter was $61.0 million, an increase from $53.0 million in the previous year. The effective tax rate was 23.9%, slightly higher than the 23.8% in the previous year.
Cash provided by operating activities was $189.7 million for the nine months ended December 31, 2024, compared to $182.0 million in the previous year.
The company reported a decrease in interest expense to $11.5 million from $16.6 million, reflecting lower average indebtedness and borrowing costs.
Prestige Consumer Healthcare continues to monitor economic conditions, including supply chain constraints and inflation, which may impact future operations.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Prestige Consumer Healthcare Inc. quarterly 10-Q report dated February 6, 2025. To report an error, please email earnings@qz.com.